Analyst Research and Recommendations: AC Immune SA (ACIU), Can-Fite BioPharma Ltd. (CANF)

AC Immune SA (NASDAQ:ACIU) tinted loss of -4.5% (-0.51 points) to US$10.83. The volume of 0.18 Million shares climbed down over an trading activity of 145.57 Million shares. EPS ratio determined by looking at last 12 month figures is -0.54. Over the same time span, the stock marked US$17.4 as its best level and the lowest price reached was US$7.16. The corporation has a market cap of US$704.49 Million.

AC Immune SA (NASDAQ:ACIU)’s earnings per share has been growing at a 0 percent rate over the past 5 year when average revenue increase was noted as 0 percent. The return on equity ratio or ROE stands at -25.2 percent while most common profitability ratio return on investment (ROI) was -19.2 percent. The company’s institutional ownership is monitored at 31.6 percent. The company’s net profit margin has achieved the current level of 0 percent and possesses 0 percent gross margin.

Daily Analyst Recommendations

A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 2 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 0 think it is Hold. Recently, analysts have updated the overall rating to 1.33. 1 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.

Can-Fite BioPharma Ltd. (NYSE:CANF) is worth US$50.25 Million and has recently fallen -4.17% to US$1.15. The latest exchange of 0.16 Million shares is below its average trading activity of 128.83 Million shares. The day began at US$1.19 but the price moved to US$1.19 at one point during the trading and finally capitulating to a session high of US$1.19. The stock tapped a 52-week high of US$2.75 while the mean 12-month price target for the shares is US$8.

Currently, the stock carries a price to earnings ratio of 0, a price to book ratio of 3.94, and a price to sales ratio of 13.9. For the past 5 years, the company’s revenue has grown 0%, while the company’s earnings per share has grown 0%. With an institutional ownership near 15.29%, it carries an earnings per share ratio of -0.26.